LULU GARCIA-NAVARRO, HOST:
This past week, the White House announced plans to allow bulk imports of cheaper medications from Canada to the United States. The idea is supported by both Democrats and Republicans, but it’s unpopular among another group, Canadians.
Marc-André Gagnon is professor of health policy at Carleton University in Canada. He thinks some of the alarm here is being stoked by the pharmaceutical companies about what would only start out as limited pilot projects for the U.S.